Annual Meeting 2015: Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis

Annual Meeting 2015: Novel JAK Inhibitor Pacritinib Proves Effective for Easing Symptoms of Myelofibrosis

EMJ

5 years
856 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Findings from the PERSIST-1 study of patients with myelofibrosis suggest that pacritinib is significantly more effective than best available therapy (BAT), which includes a range of off-label treatments. At 24 weeks of treatment, 19.1% of patients on the pacritinib arm experienced spleen shrinkage, compared to only 4.7% of patients on the BAT arm. Presented by Ruben A. Mesa, MD, Mayo Clinic Cancer Center, Scottsdale, AZ, at ASCO 2015 European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay